Aigen Investment Management LP Invests $216,000 in Alkermes plc (NASDAQ:ALKS)

Aigen Investment Management LP bought a new stake in Alkermes plc (NASDAQ:ALKS) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 7,734 shares of the company’s stock, valued at approximately $216,000.

Several other large investors have also modified their holdings of ALKS. V Square Quantitative Management LLC acquired a new stake in Alkermes during the third quarter valued at approximately $29,000. Signaturefd LLC lifted its stake in Alkermes by 51.2% during the second quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after purchasing an additional 480 shares during the last quarter. Hexagon Capital Partners LLC boosted its holdings in Alkermes by 3,841.0% in the second quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after purchasing an additional 1,498 shares during the period. GAMMA Investing LLC increased its stake in Alkermes by 44.4% during the second quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock valued at $55,000 after purchasing an additional 703 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alkermes during the second quarter worth $116,000. Institutional investors own 95.21% of the company’s stock.

Insider Activity at Alkermes

In related news, EVP Craig C. Hopkinson sold 58,996 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the completion of the transaction, the executive vice president now owns 83,300 shares of the company’s stock, valued at $2,505,664. This trade represents a 41.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 4.89% of the company’s stock.

Alkermes Stock Down 0.6 %

Alkermes stock opened at $28.19 on Friday. Alkermes plc has a 52 week low of $22.06 and a 52 week high of $32.88. The stock has a market cap of $4.56 billion, a price-to-earnings ratio of 14.46, a PEG ratio of 0.98 and a beta of 0.47. The company’s 50-day moving average price is $27.79 and its two-hundred day moving average price is $26.22. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Mizuho lifted their price target on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday. Robert W. Baird upped their target price on Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Cantor Fitzgerald cut their price target on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. HC Wainwright restated a “neutral” rating and set a $37.00 price objective on shares of Alkermes in a research note on Friday, October 25th. Finally, The Goldman Sachs Group cut their target price on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.42.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.